Off the Shelf Cell Therapies for Bone Marrow Transplantation with Ossium Health’s Kevin Caldwell

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Kevin Caldwell, CEO, Co-Founder & President of Ossium Health, a biotechnology company advancing the first off-the-shelf bone marrow therapy derived from deceased organ donors. The treatment is designed to address longstanding clinical and logistical challenges in allogeneic bone marrow transplantation. Kevin Caldwell has led Ossium Health in building more than 50 strategic partnerships with biopharmaceutical companies and helped secure a transformative federal contract with BARDA (Biomedical Advanced Research and Development Authority). Prior to founding Ossium, Kevin served as an Engagement Manager at McKinsey’s San Francisco office where he advised clients in the biotechnology and healthcare sectors, and prior to that, served as a Senior Investment Associate at Bridgewater Associates where he did quantitative research for the firm’s global macro investments. Kevin holds degrees in Physics and Economics from MIT and a JD from Harvard Law School. Tune in to learn about how about the landscape of cell therapy and allogeneic transplantation, including the translation of off-the-shelf cellular therapies into clinical practice and how emerging models could reshape bone marrow transplantation workflows. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured